Jump to content

Science 37

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Citation bot (talk | contribs) at 22:10, 16 October 2020 (Add: work, bibcode. Removed parameters. Some additions/deletions were actually parameter name changes. | You can use this bot yourself. Report bugs here. | Suggested by AManWithNoPlan | All pages linked from cached copy of User:AManWithNoPlan/sandbox4 | via #UCB_webform_linked 929/3254). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Science 37
Company typePrivate
IndustryClinical research
Founded2014
FoundersNoah Craft and Belinda Tan
Websitewww.science37.com

Science 37 is an American clinical research company.

History

Science 37 was founded in 2014[1] by company CEO Noah Craft and Chief Medical Officer Belinda Tan, working out of LA BioMed at Harbor-UCLA Medical Center.[2] It received its initial round of funding in 2015, with a $6.5 million investment.[3] In 2016 the company’s second round of financing resulted in $31 million in funding, and a 2017 round of financing resulted in $29 million.[4][5] Science 37 has developed the Network Oriented Research Assistant platform, also known as the NORA platform, which includes video chat, digital self-photography, data collection, and electronic consent. Together, these features are used to conduct “site-less” trials.[6] The platform also aids researchers in finding and contacting potential participants, and scheduling trial participants for in-home activities like questionnaires, mobile nurse visits,[7] and door-step study medicine delivery.[8]

Partnerships

In 2015 Science 37 began working with Genentech in the recruitment of trial participants.[9] In 2017 Science 37 then completed a site-less trial for AOBiome Therapeutics. This was the first “interventional, randomized, placebo-controlled trial” to be completed virtually.[6] That year Science 37 also began planning site-less trials for Sanofi[10] and Otsuka Pharmaceutical.[11]

In 2018 the company partnered with Novartis to plan several site-less clinical trials. Novartis also owns 10% of Science 37 from an early-stage investment in the company.[12] Science 37 was already in the process of conducting trials with Novartis in acne, cluster headaches, and fatty liver disease.[2]

References

  1. ^ "GV joins $29 million investment into Science 37 to bring clinical trials to the home". Venture Beat. 25 April 2017.
  2. ^ a b "Science 37, Novartis to Conduct Virtual Clinical Trials". labusinessjournal.com. Los Angeles Business Journal.
  3. ^ "Novartis joint venture helps virtual trial CRO to $6.5m fundraising round". Outsourcing Pharmaceuticals.
  4. ^ "Science37 aims to democratize clinical research with a fresh $29 million in growth funding". techcrunch.com. TechCrunch.
  5. ^ "Novartis scaling 'site-less' trials through expanded Science 37 alliance".
  6. ^ a b "Science 37 concludes its first fully virtual clinical trial". Mobile Health News. 24 October 2017.
  7. ^ Landhuis, Esther (1 April 2018). "Outsourcing is in". Nature. 556 (7700): 263–265. Bibcode:2018Natur.556..263L. doi:10.1038/d41586-018-04163-8. PMID 29643487.
  8. ^ Herper, Matthew. "AI. Telemedicine. Quantum. New Novartis Boss Says Tech Will Finally Change The Drug Biz". Forbes.
  9. ^ "Here's what clinical trial utopia may look like". medcitynews.com. MedCity News.
  10. ^ "Sanofi launches new virtual trials offering with Science 37". www.fiercebiotech.com. FierceBiotech.
  11. ^ "Otsuka works with Science 37 and more digital health deals". Mobile Health News. 8 December 2017.
  12. ^ "Novartis joins forces with LA tech company Science 37 to launch virtual clinical trials". endpts.com.

www.science37.com